NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

NTRK融合遺傳基因陽性癌症:機會評估,市場動態,流行病學研究,開發平台分析(2021年下半年)

NTRK Gene Fusion Positive Cancers -Opportunity Assessments, Market Dynamics, Epidemiological Studies, and Pipeline Analytics H2 2021

出版商 GervanoRA Data Services LLP 商品編碼 1024217
出版日期 內容資訊 英文 350 Pages
商品交期: 3-5個工作天內
價格
NTRK融合遺傳基因陽性癌症:機會評估,市場動態,流行病學研究,開發平台分析(2021年下半年) NTRK Gene Fusion Positive Cancers -Opportunity Assessments, Market Dynamics, Epidemiological Studies, and Pipeline Analytics H2 2021
出版日期: 2021年08月11日內容資訊: 英文 350 Pages
簡介

本報告提供NTRK融合遺傳基因陽性癌症市場調查,彙整市場及疾病概要,市場趨勢,流行病學調查,進行中的研究開發概要,新加入企業的市場佔有率預測及價格策略,風險調整淨現值(r-NPV)分析,開發階段·給藥途徑·作用機制·藥物類別·分子類型·標的·適應症·企業類型·各地區的開發平台(管線)的概述及比較分析,未滿足需求,開發平台藥物的專利趨勢,到2030年前的市場預測,治療領域的交易趨勢等資料。

目錄

第1章 簡介

第2章 摘要整理

第3章 NTRK融合遺傳基因陽性癌症的概要與流行病學研究

第4章 NTRK融合遺傳基因陽性癌症的市場規模的變化與預測(2020年∼2030年)

第5章 開發平台(管線)的洞察和基準預測

第6章 NTRK融合遺傳基因陽性癌症的交易趨勢

第7章 NTRK融合遺傳基因陽性癌症開發平台藥物的專利比較分析

第8章 風險調整淨現值(r-NPV)分析

第9章 競爭機會的評估

目錄
Product Code: GERPH1903

GervanoRA's pipeline analysis and opportunity assessment report "NTRK Gene Fusion Positive Cancers - Opportunity Assessments, Market Dynamics, Epidemiological Studies, and Pipeline Analytics H2 2021" analysed and assessed NTRK Gene Fusion Positive Cancers pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in NTRK Gene Fusion Positive Cancers drugs industry.

The report has been divided into segments like Disease Overview, Market Overview, Pipeline Analytics to provide in depth insights about the market dynamics and ongoing R&D in the NTRK Gene Fusion Positive Cancers area. The report provides detailed insights about all the pipeline molecules in different stages of development and all the companies which are actively involved in NTRK Gene Fusion Positive Cancers drugs industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Analytics by Stage of development, Pipeline Analytics by Route of Administration, Pipeline Analytics by Geography, Pipeline Analytics by Mechanism of Action, Pipeline Analytics by Drug Class, Pipeline Analytics by Molecule Type, Pipeline Analytics by Target and Pipeline Analytics by Company Type.

The report delivers an in-depth understanding of the NTRK Gene Fusion Positive Cancers historical and forecasted epidemiology based market trends Worldwide, the United States, EU9 (Poland, Russia, Switzerland, Sweden, Italy, Germany, Austria, France, and United Kingdom) and China. A detailed analytics on the Current NTRK Gene Fusion Positive Cancers Market (2020) and the Forecasted NTRK Gene Fusion Positive Cancers Market until the year 2030 for the regions have been provided.

Growth opportunities in the report have been provided by performing a competitive and comparative analysis on the Emerging companies in the domain based on In-Licensing opportunities, Out-Licensing opportunities, Corporate Partnering opportunities and funding opportunities. The report even aimed to conduct the Risk-Adjusted Net Present Value (RNPV) Analysis with its Excel based r-NPV analysis model to help companies in licensing negotiations, technology valuations and pipeline asset valuation and establishing the value for licensing deal. It also aims to provide the sales potential of the drugs along with the new drugs pricing and pricing strategies.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

  • Epidemiological Studies - Historical Trends and Probabilistic Epidemiology Forecast
  • Epidemiology Based Market Estimations - Current Market Value and Market Forecast
  • Plotting of the Anticipated Market Share for the New Entrants
  • Pricing Strategies of New Entrants Supported Through KOL Insights
  • Risk-Adjusted Net Present Value (RNPV) Analysis
  • Comparative Pipeline Insights and Benchmarking Snapshots by HSD, Geography, RoA, Drug Class, MoA, Molecule Target, Molecule Type
  • Unmet Needs and Opportunities
  • Comparative Patent Analytics of NTRK Gene Fusion Positive Cancers Pipeline Drugs
  • Competitive Opportunity Assessments of the Active Players in the NTRK Gene Fusion Positive Cancers Therapeutic Space by Partnering, Licensing and Funding Opportunities
  • Deals Activities of NTRK Gene Fusion Positive Cancers Therapeutic Space

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: NTRK GENE FUSION POSITIVE CANCERS OVERVIEW AND EPIDEMIOLOGICAL STUDIES

CHAPTER 4: NTRK GENE FUSION POSITIVE CANCERS CURRENT MARKET VALUE AND FORECAST 2020 - 2030

CHAPTER 5: PIPELINE INSIGHTS AND BENCHMARKING OUTLOOK

CHAPTER 6: DEALS ACTIVITIES OF NTRK GENE FUSION POSITIVE CANCERS COMPETITIVE SPACE

CHAPTER 7: COMPARATIVE PATENT ANALYTICS OF NTRK GENE FUSION POSITIVE CANCERS PIPELINE DRUGS

CHAPTER 8: RISK-ADJUSTED NET PRESENT VALUE (R-NPV) ANALYSIS

CHAPTER 9: COMPETITIVE OPPORTUNITY ASSESSMENTS

LIST OF TABLES (COMPLETE LIST CAN BE FOUND IN FULL LENGTH REPORT)

  • TABLE 01: REPORT HIGHLIGHTS IN NUMERICALS
  • TABLE 02: MARKET RESEARCH DATA ON APPROVED NTRK GENE FUSION POSITIVE CANCERS DRUGS (USD)
  • TABLE 03: ESTIMATED AVERAGE SELLING PRICES OF FILED AND LATE-CLINICAL STAGE TRK TARGETED PIPELINE DRUGS
  • TABLE 04: PERCEIVED VALUE OF NTRK GENE FUSION POSITIVE CANCERS PRESCRIPTION DRUG BY COMPETITIVE BENCHMARKING
  • TABLE 05: FINANCING DEALS IN NTRK GENE FUSION POSITIVE CANCERS THERAPEUTIC AREA
  • TABLE 06: LICENSING DEALS IN NTRK GENE FUSION POSITIVE CANCERS THERAPEUTIC AREA
  • TABLE 07: MERGER AND ACQUISITION DEALS IN NTRK GENE FUSION POSITIVE CANCERS THERAPEUTIC AREA
  • TABLE 08: COLLABORATION DEALS IN NTRK GENE FUSION POSITIVE CANCERS THERAPEUTIC AREA
  • TABLE 09: NTRK GENE FUSION POSITIVE CANCERS PIPELINE DRUGS BY STAGE OF DEVELOPMENT
  • TABLE 10: NTRK GENE FUSION POSITIVE CANCERS PRE-REGISTRATION STAGE PIPELINE DRUGS
  • TABLE 11: NTRK GENE FUSION POSITIVE CANCERS PHASE III PIPELINE DRUGS
  • TABLE 12: NTRK GENE FUSION POSITIVE CANCERS PHASE II PIPELINE DRUGS
  • TABLE 13: NTRK GENE FUSION POSITIVE CANCERS PHASE I PIPELINE MOLECULES
  • TABLE 14: NTRK GENE FUSION POSITIVE CANCERS PRE-CLINICAL PIPELINE MOLECULES
  • TABLE 15: TERMINATED NTRK GENE FUSION POSITIVE CANCERS PIPELINE MOLECULES
  • TABLE 16: PIPELINE DRUGS ALONG WITH ANTICIPATED REGION OF APPROVAL
  • TABLE 17: CLINICAL STAGE PIPELINE DRUGS WITH ORAL ROUTE OF ADMINISTRATION
  • TABLE 18: PIPELINE DRUGS WITH THEIR MOLECULAR TARGET RECEPTORS
  • TABLE 19: PIPELINE DRUGS WITH THEIR TARGETED INDICATIONS
  • TABLE 20: TRK TARGETED PIPELINE DRUGS ANALYTICS BY COMPANY TYPE

LIST OF FIGURES (COMPLETE LIST CAN BE FOUND IN FULL LENGTH REPORT)

  • FIGURE 01: KEY EVENTS IN THE TRK BASED THERAPIES COMPETITIVE SPACE
  • FIGURE 02: FORECASTED ANNUAL INCREASE IN NTRK GENE FUSION POSITIVE CANCERS DRUG MARKET
  • FIGURE 03: NTRK GENE FUSION POSITIVE CANCERS TOTAL MARKET SHARE
  • FIGURE 04: COMPARISON OF TRK INHIBITORS MARKET TARGETING NTRK FUSION CANCERS & OTHER INDICATIONS
  • FIGURE 05: COMPARISON OF ESTIMATED SALES FOR THE KEY LATE CLINICAL STAGE DRUGS
  • FIGURE 06: COMPARISON OF EXPECTED PEAK SALES OF SITRAVATINIB AND REPOTRECTINIB
  • FIGURE 07: ESTIMATED MARKET SHARE OF TRK INHIBITORS TARGETING NTRK GENE FUSION POSITIVE CANCERS IN 2029
  • FIGURE 08: TRK INHIBITORS DRUG PIPELINE SCENARIO, DRUG CANDIDATES VS HSD AND COMPANY TYPE
  • FIGURE 09: SHARE OF PREVALENCE OF THREE MAJOR CANCERS WITH NTRK GENE FUSIONS - WORLDWIDE
  • FIGURE 10: SHARE OF PREVALENCE OF OTHER CANCERS WITH NTRK GENE FUSIONS - WORLDWIDE
  • FIGURE 11: NEW CASES OF NTRK GENE FUSION-POSITIVE LUNG CANCER - WORLDWIDE
  • FIGURE 12: PREVALENCE RATE PER 100000 OF NTRK GENE FUSION-POSITIVE LUNG CANCER - WORLDWIDE
  • FIGURE 13: PREVALENCE OF NTRK GENE FUSION-POSITIVE BREAST CANCER - WORLDWIDE
  • FIGURE 14:PREVALENCE RATE PER 100000 OF NTRK GENE FUSION-POSITIVE BREAST CANCER - WORLDWIDE
  • FIGURE 15: PREVALENCE OF NTRK GENE FUSION-POSITIVE SBC - WORLDWIDE
  • FIGURE 16: PREVALENCE RATE PER 100000 OF NTRK GENE FUSION-POSITIVE SBC - WORLDWIDE
  • FIGURE 17: PREVALENCE OF NTRK GENE FUSION-POSITIVE COLORECTAL CANCER - WORLDWIDE
  • FIGURE 18: PREVALENCE OF NTRK GENE FUSION-POSITIVE COLORECTAL CANCER - US AND EUROPE
  • FIGURE 19: COMPARISON OF PREVALENCE POPULATION OF OTHER CANCERS WITH NTRK GENE FUSIONS - WORLWIDE
  • FIGURE 20: SHARE OF PREVALENCE OF OTHER CANCERS WITH NTRK GENE FUSIONS - US
  • FIGURE 21: PREVALENCE OF NTRK GENE FUSION-POSITIVE GBM - WORLDWIDE
  • FIGURE 22: PREVALENCE OF NTRK GENE FUSION-POSITIVE GBM - USA AND EUROPE
  • FIGURE 23: PREVALENCE OF NTRK GENE-FUSION POSITIVE ASTROCYTOMA - WORLDWIDE
  • FIGURE 24: PREVALENCE OF NTRK GENE-FUSION POSITIVE ASTROCYTOMA - US AND EUROPE
  • FIGURE 25: PREVALENCE OF NTRK GENE FUSION-POSITIVE HNSCC - WORLDWIDE
  • FIGURE 26: PREVALENCE OF NTRK GENE FUSION-POSITIVE HNSCC - US AND EUROPE
  • FIGURE 27: PREVALENCE OF NTRK GENE FUSION-POSITIVE APPENDICEAL CANCER - WORLDWIDE
  • FIGURE 28: PREVALENCE OF NTRK GENE FUSION-POSITIVE APPENDICEAL CANCER - US AND EUROPE
  • FIGURE 29: PREVALENCE OF NTRK GENE FUSION-POSITIVE THYROID CANCERS - WORLDWIDE
  • FIGURE 30: PREVALENCE OF NTRK GENE FUSION-POSITIVE THYROID CANCERS - US AND EUROPE
  • FIGURE 31: PREVALENCE OF NTRK GENE FUSION-POSITIVE CHOLANGIOCARCINOMA - WORLDWIDE
  • FIGURE 32: PREVALENCE OF NTRK GENE FUSION-POSITIVE CHOLANGIOCARCINOMA - US AND EUROPE
  • FIGURE 33: PREVALENCE OF NTRK GENE FUSION-POSITIVE PANCREATIC CANCER - WORLDWIDE
  • FIGURE 34: PREVALENCE OF NTRK GENE FUSION-POSITIVE PANCREATIC CANCER - US AND EUROPE
  • FIGURE 35: PREVALENCE OF NTRK GENE FUSION-POSITIVE MASC - WORLDWIDE
  • FIGURE 36: PREVALENCE OF NTRK GENE FUSION-POSITIVE MASC - US AND EUROPE
  • FIGURE 37: PREVALENCE OF NTRK GENE FUSION-POSITIVE INFANTILE FIBROSARCOMA - WORLDWIDE
  • FIGURE 38: PREVALENCE OF NTRK GENE FUSION-POSITIVE INFANTILE FIBROSARCOMA - USA
  • FIGURE 39: PREVALENCE OF NTRK GENE FUSION-POSITIVE CONGENITAL MESOBLASTIC NEPHROMA - WORLDWIDE
  • FIGURE 40: PREVALENCE OF NTRK GENE FUSION-POSITIVE CONGENITAL MESOBLASTIC NEPHROMA - USA
  • FIGURE 41: PREVALENCE OF NTRK GENE FUSION-POSITIVE GASTROINTESTINAL STROMAL TUMORS - WORLDWIDE
  • FIGURE 42: PREVALENCE OF NTRK GENE FUSION-POSITIVE GASTROINTESTINAL STROMAL TUMORS - US
  • FIGURE 43: PREVALENCE OF NTRK GENE FUSION-POSITIVE MELANOMA - WORLDWIDE
  • FIGURE 44: PREVALENCE OF NTRK GENE FUSION-POSITIVE MELANOMA - US AND EUROPE
  • FIGURE 45: PREVALENCE OF NTRK GENE FUSION-POSITIVE SPITZOID MELANOMA - WORLDWIDE
  • FIGURE 46: PREVALENCE OF NTRK GENE FUSION-POSITIVE SPITZOID MELANOMA - US AND EUROPE
  • FIGURE 47: PREVALENCE OF NTRK GENE FUSION-POSITIVE SARCOMAS - WORLDWIDE
  • FIGURE 48: PREVALENCE OF NTRK GENE FUSION-POSITIVE SARCOMAS - USA
  • FIGURE 49:PREVALENCE OF NTRK GENE FUSION-POSITIVE LUNG CANCER - UNITED STATES
  • FIGURE 50: PREVALENCE RATE PER 100000 OF NTRK GENE FUSION-POSITIVE LUNG CANCER
  • FIGURE 51:PREVALENCE OF NTRK GENE FUSION-POSITIVE BREAST CANCER - UNITED STATES
  • FIGURE 52: PREVALENCE RATE PER 100000 OF NTRK GENE FUSION-POSITIVE BREAST CANCER
  • FIGURE 53: PREVALENCE AND PREVALENCE RATE PER 100000 OF NTRK GENE FUSION-POSITIVE SBC - US
  • FIGURE 54:PREVALENCE OF NTRK GENE FUSION-POSITIVE COLORECTAL CANCERS - US
  • FIGURE 55: PREVALENCE OF NTRK GENE FUSION-POSITIVE GBM - US
  • FIGURE 56: PREVALENCE OF NTRK GENE FUSION-POSITIVE ASTROCYTOMA - US
  • FIGURE 57: PREVALENCE OF NTRK GENE FUSION-POSITIVE HNSCC - US
  • FIGURE 58: PREVALENCE OF NTRK GENE FUSION-POSITIVE APPENDICEAL CANCER - US
  • FIGURE 59: PREVALENCE OF NTRK GENE FUSION-POSITIVE THYROID CANCER - US
  • FIGURE 60: PREVALENCE OF NTRK GENE FUSION-POSITIVE CHOLANGIOCARCINOMA - US